Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.63 |
| ▸ | HTR7 | P34969 | 13/20 | 0.57 |
| ▸ | HTR1A | P08908 | 12/20 | 0.57 |
| ▸ | HTR2A | P28223 | 12/20 | 0.57 |
| ▸ | HTR6 | P50406 | 12/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302359 | 0.88 | HTR7 (0.62) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL6636785 | 0.85 | HTR7 (0.56) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL1700315 | 0.84 | OPRM1 (0.58) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL13806582 | 0.82 | OPRM1 (0.59) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL25317024 | 0.82 | HTR7 (0.62) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL4952229 | 0.82 | OPRL1 (0.60) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL21626818 | 0.82 | OPRM1 (0.44) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL25362517 | 0.81 | OPRM1 (0.56) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL25362520 | 0.81 | OPRM1 (0.56) | OPRM1OPRK1OPRL1HTR7HTR1A | |
| SCHEMBL29622026 | 0.81 | BACE1 (0.68) | OPRM1OPRK1OPRL1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947678-B2 | Heterocyclic benzodiazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100113419-A1 | CGRP RECEPTOR ANTAGONISTS | BURGEY CHRISTOPHER S | 2010-05-06 | — | — | US | disclosed |
| US-7659264-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090105228-A1 | Heterocyclic benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
| US-20080070899-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | OPRM1 4336/4885OPRK1 4267/4885OPRL1 4241/4885 |
| US-20090105228-A1 | Heterocyclic benzodiazepine cgrp receptor antagonists | BDKRB2, BDKRB1, CCKBR | OPRM1 45/4885OPRK1 39/4885OPRL1 24/4885 |
| US-20080070899-A1 | Cgrp Receptor Antagonists | BDKRB1, CCKBR, CALCRL | OPRM1 94/4885OPRK1 35/4885OPRL1 15/4885 |
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | OPRM1 39/4885OPRK1 35/4885OPRL1 14/4885 |
| US-20100113419-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | OPRM1 120/4885OPRK1 43/4885OPRL1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.